Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Multimedia technology for independence and participation for people with dementia

MYLIFE

The objective of Mylife is to support independence for older people with reduced cognitive function by giving them access to simple and intuitive services that are adapted to their individual needs and wishes. The ambition of the Mylife project is to provide network-based access to, and management of, commercially and/or freely available software...

Funding Programme
Start Date
End Date
Total Funding
€ 1 059 973
European Countries Involved

Music Interventions for Dementia and Depression in ELderly care (MIDDEL): International cluster-randomised trial

MIDDEL

Many older adults living in residential care homes suffer from dementia and depression. MIDDEL aims to determine if music interventions can help. Specifically, this trial will provide robust and generalisable results concerning the comparative effects of group music therapy (GMT), recreational choir singing (RCS), their combination, or standard...

Funding Programme
Start Date
End Date
Total Funding
€ 2 600 000
European Countries Involved

NAD+ International Scientist-training

NADIS

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to...

Funding Programme
Start Date
End Date
Total Funding
€ 2 530 832
European Countries Involved

Nanofluidics for label-free detection of exosomes and protein aggregates in neurodegenerative disease research

EXO-CHIP

Microfluidics have become a powerful tool in biotechnology and life sciences, whereas the nanofluidic regime remains widely unused in industry and the clinical environment. Especially protein misfolding diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease, recently experience a growing demand for single-molecule detection capabilities...

Funding Programme
Start Date
End Date
Total Funding
€ 210 911
European Countries Involved

PRE-CLINICAL GENOTYPE-PHENOTYPE PREDICTORS OF ALZHEIMER’S DISEASE AND OTHER DEMENTIA

APGeM

Alzheimer’s disease, Lewy-body dementias (including Parkinson’s disease) and other neurodegenerative dementias are major causes of disease, reduced patient- and caregiver quality of life, and increasing societal health costs. All have lengthy (decades) pre-dementia- and pre-clinical stages, but patients will have suffered irreversible brain damage...

Funding Programme
Start Date
End Date
Total Funding
€ 1 730 000
European Countries Involved

Precision Medicine Interventions in Alzheimer’s Disease

PMI-AD

Alzheimer’s disease (AD) is characterized by brain nerve cell death and dementia, but before dementia, leading up to these final and irreversible end-points we first see loss of synapses, which are the contacts between nerve cells allowing us to think, learn and function as independent beings. Coincident with early synaptic loss we also see...

Funding Programme
Start Date
End Date
Total Funding
€ 2 000 000
European Countries Involved

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

PREDICTOM

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care...

Funding Programme
Start Date
End Date
Total Funding
€ 8 449 326

Prediction, Monitoring and Personalized Recommendations for Prevention and Relief of Dementia and Frailty

COMFORTAGE

COMFORTAGE is a joint effort of medical experts (i.e., neurologists, psychiatrists, neuropsychologists, nurses, memory clinics), social scientists and humanists, technical experts (i.e., data scientists, AI experts, robotic experts) and Digital Innovation Hubs to establish a pan European framework for Community-based, Integrated and People-Centric...

Funding Programme
Start Date
End Date
Total Funding
€ 17 591 490

Prevention and Remediation of Insulin Multimorbidity in Europe

PRIME

PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 001
European Countries Involved

PROMOTING MENTAL WELLBEING IN THE AGEING URBAN POPULATION: DETERMINANTS, POLICIES AND INTERVENTIONS IN EUROPEAN CITIES

MINDMAP

Major depressive disorder, dementia, anxiety disorders, and substance abuse affect a substantial part of the European older population. Over 70% of Europeans reside in cities, and this percentage will increase in the next decades. Urbanization and ageing have enormous implications for public mental health. Cities pose major challenges for older...

Funding Programme
Start Date
End Date
Total Funding
€ 5 743 160
European Countries Involved

Propagation behaviour of peripheral amyloid-β towards brain structures: effects of the blood-brain barrier

PROP-AD

Alzheimer's disease is a disease in which specific peptides, so-called beta-amyloids, accumulate in the brain, leading to the destruction of neurons and the resulting clinical functional effects, e.g. memory and orientation problems. Discussions are ongoing as to whether or not Alzheimer's disease may be transmissible between individuals and could...

Funding Programme
Start Date
End Date
Total Funding
€ 1 746 751
European Countries Involved

Self-management and HeAlth Promotion in Early-stage dementia with e-learning for carers – A randomised controlled trial

SHAPE

We will develop and validate an intervention (SHAPE) in 330 people with mild dementia; combining self-management, health promotion, and e-learning. The study is a multi-site, randomised, controlled, single-blinded trial with parallel groups. The intervention group is compared with treatment as usual (TAU). The primary outcome is to evaluate the...

Funding Programme
Start Date
End Date
Total Funding
€ 2 887 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).